Lower doses produced more modest reductions: 4 mg dose: approximately 8.7% mean weight reduction 0.5 mg dose: approximately 2.0% mean weight reduction Placebo: a small mean weight gain of approximately 2.0% Readers should note that these figures are drawn from a single phase 2 trial with a relatively small sample size and 24-week duration
The same principle applies to customer service: staff should be trained to answer policy questions with specificity, not canned platitudes, and to escalate complex concerns with transparent handoffs
The fiber timing rule Do not take fiber supplements within 1-2 hours of your GLP-1 medication
In the SURMOUNT5 trial, participants lost an average of 20.2 % of their baseline body weight over 72 weeks with tirzepatide, with a greater proportion achieving weight-loss thresholds of 1525 % compared with semaglutide
Complete weight maintenance without pharmacological support proves difficult for most patients, reflecting the biological nature of obesity as a chronic disease requiring ongoing management
Preclinical and mechanistic studies have shown promise
